Format

Send to:

Choose Destination

Refractory Urothelial Carcinoma

MedGen UID:
1659806
•Concept ID:
C4725681
•
Neoplastic Process

Definition

Urothelial carcinoma that does not respond to treatment. [from NCI]

Professional guidelines

PubMed

Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development.
Powles T, Necchi A, Rosen G, Hariharan S, Apolo AB
Clin Genitourin Cancer 2018 Apr;16(2):117-129. Epub 2017 Dec 6 doi: 10.1016/j.clgc.2017.11.002. PMID: 29325739Free PMC Article
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP).
Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ
Urol Oncol 2003 Sep-Oct;21(5):342-8. doi: 10.1016/s1078-1439(02)00300-9. PMID: 14670540

Recent clinical studies

Etiology

Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.
Bitting RL, Tooze JA, Goodman M, Vile DC, Brown JM, Thomas CY, Neve M, Kooshki M, Addo S, Triozzi PL, Dubey P
Cancer Res Commun 2024 Feb 26;4(2):530-539. doi: 10.1158/2767-9764.CRC-23-0436. PMID: 38345536Free PMC Article
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Matsubara N, de Wit R, Balar AV, Siefker-Radtke AO, Zolnierek J, Csoszi T, Shin SJ, Park SH, Atduev V, Gumus M, Su YL, Karaca SB, Cutuli HJ, Sendur MAN, Shen L, O'Hara K, Okpara CE, Franco S, Moreno BH, Grivas P, Loriot Y
Eur Urol 2024 Mar;85(3):229-238. Epub 2023 Sep 29 doi: 10.1016/j.eururo.2023.08.012. PMID: 37778952
Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Ito K, Kita Y, Kobayashi T
Int J Urol 2023 Sep;30(9):696-703. Epub 2022 Dec 9 doi: 10.1111/iju.15101. PMID: 36482843
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H
BJU Int 2023 Apr;131(4):477-485. Epub 2022 Sep 26 doi: 10.1111/bju.15893. PMID: 36098556
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Yumioka T, Honda M, Shimizu R, Teraoka S, Yamaguchi N, Kawamoto B, Iwamoto H, Morizane S, Hikita K, Takenaka A
Anticancer Res 2021 Nov;41(11):5767-5773. doi: 10.21873/anticanres.15393. PMID: 34732450

Diagnosis

Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H
BJU Int 2023 Apr;131(4):477-485. Epub 2022 Sep 26 doi: 10.1111/bju.15893. PMID: 36098556

Therapy

Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma.
Bitting RL, Tooze JA, Goodman M, Vile DC, Brown JM, Thomas CY, Neve M, Kooshki M, Addo S, Triozzi PL, Dubey P
Cancer Res Commun 2024 Feb 26;4(2):530-539. doi: 10.1158/2767-9764.CRC-23-0436. PMID: 38345536Free PMC Article
Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial.
Matsubara N, de Wit R, Balar AV, Siefker-Radtke AO, Zolnierek J, Csoszi T, Shin SJ, Park SH, Atduev V, Gumus M, Su YL, Karaca SB, Cutuli HJ, Sendur MAN, Shen L, O'Hara K, Okpara CE, Franco S, Moreno BH, Grivas P, Loriot Y
Eur Urol 2024 Mar;85(3):229-238. Epub 2023 Sep 29 doi: 10.1016/j.eururo.2023.08.012. PMID: 37778952
Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
Ito K, Kita Y, Kobayashi T
Int J Urol 2023 Sep;30(9):696-703. Epub 2022 Dec 9 doi: 10.1111/iju.15101. PMID: 36482843
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H
BJU Int 2023 Apr;131(4):477-485. Epub 2022 Sep 26 doi: 10.1111/bju.15893. PMID: 36098556
Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy.
Marchioni M, Nazzani S, Preisser F, Bandini M, Karakiewicz PI
Expert Rev Anticancer Ther 2018 Apr;18(4):377-387. Epub 2018 Feb 15 doi: 10.1080/14737140.2018.1439744. PMID: 29429376

Prognosis

Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel.
Jackson-Spence F, Ackerman C, Jones R, Toms C, Jovaisaite A, Young M, Hussain S, Protheroe A, Birtle A, Chakraborti P, Huddart R, Jagdev S, Bahl A, Sundar S, Crabb S, Powles T, Szabados B
Urol Oncol 2024 Nov;42(11):372.e1-372.e10. Epub 2024 Jul 17 doi: 10.1016/j.urolonc.2024.05.015. PMID: 39025719
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on Neutrophil-Lymphocyte Ratio Fluctuation and Liver Metastases.
Nishio K, Higashio T, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Tsuchida S, Matsuda T, Tsujino T, Nishimura K, Tokushige S, Nakamori K, Uchimoto T, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Azuma H
Oncology 2024;102(6):457-464. Epub 2023 Oct 13 doi: 10.1159/000534554. PMID: 37839399
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P, Ravaud A, Durán I, Szabados B, Castellano D, Giannatempo P, Loriot Y, Carles J, Anguera Palacios G, Lefort F, Raggi D, Gross Goupil M, Powles T, Van der Heijden MS
Eur Urol 2020 Feb;77(2):269-276. Epub 2019 Nov 5 doi: 10.1016/j.eururo.2019.10.004. PMID: 31699525
Novel strategies for treating relapsed/refractory urothelial carcinoma.
Iyer G, Milowsky MI, Bajorin DF
Expert Rev Anticancer Ther 2010 Dec;10(12):1917-32. doi: 10.1586/era.10.182. PMID: 21110758Free PMC Article
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP).
Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ
Urol Oncol 2003 Sep-Oct;21(5):342-8. doi: 10.1016/s1078-1439(02)00300-9. PMID: 14670540

Clinical prediction guides

Biomarkers associated with survival in patients with platinum-refractory urothelial carcinoma treated with paclitaxel.
Jackson-Spence F, Ackerman C, Jones R, Toms C, Jovaisaite A, Young M, Hussain S, Protheroe A, Birtle A, Chakraborti P, Huddart R, Jagdev S, Bahl A, Sundar S, Crabb S, Powles T, Szabados B
Urol Oncol 2024 Nov;42(11):372.e1-372.e10. Epub 2024 Jul 17 doi: 10.1016/j.urolonc.2024.05.015. PMID: 39025719
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Uchimoto T, Fukushima T, Komura K, Fukuokaya W, Adachi T, Hashimoto T, Yoshizawa A, Nakamura K, Yano Y, Nishimura K, Nishio K, Nakamori K, Iwatani K, Yamamoto S, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Miki J, Kimura T, Ohno Y, Shiroki R, Egawa S, Azuma H
BJU Int 2023 Apr;131(4):477-485. Epub 2022 Sep 26 doi: 10.1111/bju.15893. PMID: 36098556
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Yumioka T, Honda M, Shimizu R, Teraoka S, Yamaguchi N, Kawamoto B, Iwamoto H, Morizane S, Hikita K, Takenaka A
Anticancer Res 2021 Nov;41(11):5767-5773. doi: 10.21873/anticanres.15393. PMID: 34732450
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P, Ravaud A, Durán I, Szabados B, Castellano D, Giannatempo P, Loriot Y, Carles J, Anguera Palacios G, Lefort F, Raggi D, Gross Goupil M, Powles T, Van der Heijden MS
Eur Urol 2020 Feb;77(2):269-276. Epub 2019 Nov 5 doi: 10.1016/j.eururo.2019.10.004. PMID: 31699525
Phase II Study of Pazopanib and Paclitaxel in Patients With Refractory Urothelial Cancer.
Narayanan S, Lam A, Vaishampayan U, Harshman L, Fan A, Pachynski R, Poushnejad S, Haas D, Li S, Srinivas S
Clin Genitourin Cancer 2016 Oct;14(5):432-437. Epub 2016 Mar 12 doi: 10.1016/j.clgc.2016.03.011. PMID: 27068017Free PMC Article

Recent systematic reviews

Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies.
Tafuri A, Smith DD, Cacciamani GE, Cole S, Shakir A, Sadeghi S, Vogelzang NJ, Quinn D, Gill PS, Gill IS
Clin Genitourin Cancer 2020 Oct;18(5):351-360.e3. Epub 2020 Jan 31 doi: 10.1016/j.clgc.2020.01.004. PMID: 32146152Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...